Conversely, IFNα therapy (blue frame), by modifying LSECs porosity, thickness, deposition of basal membrane and GCX depth, builds up a vascular antimetastatic barrier (5), that impairs CRC trans-sinusoidal migration, promoting intravascular containment of invading tumor cells (6) that together with IFNα-mediated increased cross-presentation and cross-priming by HECs/LSEC, will lead to naïve CD8+ T cell activation and secondary generation of long-term antitumor immunity and protection from secondary tumor challenge (7). The gene discussed is IFNA1; the disease is neoplasm.